Relma-Cel Continues to Elicit Responses in Chinese Patients With R/R Mantle Cell Lymphoma
Relmacabtagene autoleucel continued to induce responses with acceptable tolerability in Chinese patients with relapsed or refractory mantle cell lymphoma.
Mantle Cell Lymphoma International Prognostic Index Key Laboratory Of Carcinogenesis Department Of Lymphoma Key Laboratory Translational Research Peking University Cancer Hospital
Source: onclive.com